Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

More than 250 million people are living with chronic hepatitis B despite the availability of
highly effective vaccines and oral antivirals. Although innate and adaptive immune cells play …

Hepatitis B virus (HBV) is a hepatotropic virus and an important human pathogen. There are
an estimated 296 million people in the world that are chronically infected by this virus, and …

Cancer is one of the deadliest non communicable diseases. Numerous anticancer
medications have been developed to target the molecular pathways driving cancer …

Resistance to anoikis is a key characteristic of many cancer cells, promoting cell survival.
However, the mechanism of anoikis in hepatocellular carcinoma (HCC) remains unknown …

Abstract N6-methyladenosine (m6A) modification, as one of the most common types of inner
RNA modification in eukaryotes, plays a multifunctional role in normal and abnormal …

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and is
often associated with a poor prognosis. The main reason for this poor prognosis is that …

Chronic infection of Hepatitis B virus (HBV) has long been recognized as a major risk factor
in the initiation and development of hepatocellular carcinoma (HCC), contributing to over …

The liver is a lymphoid organ with unique immunological properties, particularly, its
predominant innate immune system. The balance between immune tolerance and immune …

The hepatitis B virus (HBV) counts as a major global health problem, as it presents a
significant causative factor for liver-related morbidity and mortality. The development of …